COMPANIESACCESS BIO, INC.
✓ Verified H1B Sponsor

ACCESS BIO, INC.

Somerset, NJEIN 460505083
TRUST SCORE
83.2
High Trust
5
FY2024 H1B Approvals
5
All-time Approvals
83.2
Trust Score / 100

TOP SPONSORED JOB CATEGORIES

Medical Scientists, Except EpidemiologistsBioengineers and Biomedical EngineersNetwork and Computer Systems Administrators

RECENT H1B FILINGS

JOB TITLELOCATIONWAGEDATE
Network and Computer Systems AdministratorsSomerset, NJ$73,070Oct 2025
Market Research Analysts and Marketing SpecialistsSomerset, NJ$28.93Oct 2025
Bioengineers and Biomedical EngineersSomerset, NJ$76,627Oct 2024
Medical Scientists, Except EpidemiologistsSomerset, NJ$67,101Oct 2024
Medical Scientists, Except EpidemiologistsSomerset, NJ$67,101Oct 2024
Bioengineers and Biomedical EngineersSomerset, NJ$76,627Oct 2024
Medical Scientists, Except EpidemiologistsSomerset, NJ$67,101Oct 2024
Medical Scientists, Except EpidemiologistsSomerset, NJ$67,101Oct 2024

SHOWING 50 MOST RECENT · SOURCE: DOL LCA PUBLIC DATA FY2024 · EIN 460505083

FREQUENTLY ASKED QUESTIONS

Does ACCESS BIO, INC. sponsor H1B visas?

Yes. ACCESS BIO, INC. has an active H1B sponsorship history with 5 total approved LCA filings on record, including 5 approvals in FY2024. Data sourced from US Department of Labor public disclosure files.

How many H1B visas has ACCESS BIO, INC. sponsored?

According to DOL LCA data, ACCESS BIO, INC. has 5 all-time H1B approvals and 5 approvals in fiscal year 2024.

What types of roles does ACCESS BIO, INC. sponsor H1B for?

ACCESS BIO, INC. most commonly sponsors H1B visas for: Medical Scientists, Except Epidemiologists, Bioengineers and Biomedical Engineers, Network and Computer Systems Administrators. This is based on their DOL Labor Condition Application filing history.

Is ACCESS BIO, INC. a reliable H1B sponsor?

ACCESS BIO, INC. has a Trust Score of 83.2/100 on KEEL, calculated from total approval volume, recency of filings, and approval consistency based on DOL LCA data.

DATA SOURCE: US DEPT. OF LABOR · LCA PUBLIC DISCLOSURE FY2023–FY2024